Livagen

Peptide bioregulators are built on a specific claim: that very short peptides extracted from — or synthesised to match — a particular organ can travel to that same organ and restore its normal function as it ages. Livagen is the liver version. It is also the peptide most often cited in the class's central claim, because the originating group published work reporting that it decondenses chromatin in lymphocytes from elderly donors — the observation their gene-activation hypothesis leans on. The proposed route is direct interaction with DNA to switch tissue-specific genes back on. That mechanism has been demonstrated to the satisfaction of the group that proposed it and essentially nobody else.

A tetrapeptide reported to induce heterochromatin decondensation in peripheral lymphocytes from elderly subjects and to activate ribosomal gene transcription, findings that form a substantial part of the evidentiary basis cited for the entire bioregulator concept. The class hypothesis holds that di-, tri- and tetrapeptides penetrate cell and nuclear membranes and bind directly to specific promoter sequences in double-stranded DNA, modulating tissue-specific transcription — a mechanism supported by molecular modelling and gel-shift work from the originating institute but not independently corroborated. Products are marketed in two chemically distinct forms: "Cytomax" preparations, which are peptide fractions extracted from the corresponding animal organ, and "Cytogen" preparations, which are defined synthetic short peptides. Published clinical evaluation is limited to small Russian studies, generally without blinding, placebo control or independent statistical review.